# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Andreas Argyrides reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Outperform and maintains $7 price...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $1...
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate o...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $1...
Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and raises the price target f...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and raises the pr...
Regulus Therapeutics announced positive results from its study related to the treatment of autosomal dominant polycystic kidney...
ALNY: 14% | Alnylam Pharmaceuticals shares are trading higher after the company announced topline results from its HELIOS-B Pha...